Trial · NCT00282438
Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
NCT00282438, Phase 1, Phase 2, Terminated, Northwestern University; results first posted 2017-02-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis. Trials, record NCT00282438. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00282438
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis
- NCT number
- NCT00282438
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Sarcoidosis
- Interventions
- Autologous hematopoietic stem cell transplantation, Allogeneic stem cell transplantation
- First posted
- 2006-01-26
- Last updated
- 2018-08-31
- Results first posted
- 2017-02-24
- Limitations and caveats
Two patients had been enrolled on trial. One underwent autologous HSCT and relapsed early after the transplant. The second participant underwent allogeneic HSCT and died 70 days after the transplant and the study has been terminated.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Presence of Toxicity | For length of hospital stay (until discharge). | Daily assessment will be made with regards to toxicity by one of the protocol investigators.National Cancer Institute Common Toxicity Criteria will be used to grade all non-hematologic toxicities. Toxicity grades as follows: 1 = Mild; 2 = Moderate; 3 = Severe and undesirable; 4 = life threatening or disabling ; 5 = Death |
| Primary | Survival | Participants are to be followed at 6 months and then yearly until 5 years | Patient has not died. |
| Primary | Time to Disease Progression | Participants are to be followed at 6 months and then yearly until 5 years | Worsening symptoms, pulmonary function studies, cardiac function and arrhythmia including EKG assessments, and neurological symptoms. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Presence of Toxicity | For length of hospital stay (until discharge). | participants | NUMBER | |
| PRIMARY | Survival | Participants are to be followed at 6 months and then yearly until 5 years | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Time to Disease Progression | Participants are to be followed at 6 months and then yearly until 5 years | months | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Presence of Toxicity | Autologous Hematopoietic Stem Cell Transplantation | 1 | participants | ||
| Presence of Toxicity | Allogeneic Stem Cell Transplantation | 1 | participants | ||
| Survival | Autologous Hematopoietic Stem Cell Transplantation | 1 | Participants | ||
| Survival | Allogeneic Stem Cell Transplantation | 0 | Participants | ||
| Time to Disease Progression | Autologous Hematopoietic Stem Cell Transplantation | 4 | months | ||
| Time to Disease Progression | Allogeneic Stem Cell Transplantation | 0 | months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Autologous Hematopoietic Stem Cell Transplantation | 1 | |
| Overall Study | STARTED | Allogeneic Stem Cell Transplantation | 1 | |
| Overall Study | COMPLETED | Autologous Hematopoietic Stem Cell Transplantation | 0 | |
| Overall Study | COMPLETED | Allogeneic Stem Cell Transplantation | 0 | |
| Overall Study | NOT COMPLETED | Autologous Hematopoietic Stem Cell Transplantation | 1 | |
| Overall Study | NOT COMPLETED | Allogeneic Stem Cell Transplantation | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Death | Infections and infestations | Autologous Hematopoietic Stem Cell Transplantation | 0 | 1 | 0 |
| serious | Death | Infections and infestations | Allogeneic Stem Cell Transplantation | 1 | 1 | 1 |
| serious | Sepsis | Infections and infestations | Autologous Hematopoietic Stem Cell Transplantation | 0 | 1 | 0 |
| serious | Sepsis | Infections and infestations | Allogeneic Stem Cell Transplantation | 1 | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Autologous Hematopoietic Stem Cell Transplantation | ||
| Total, all-cause mortality | Allogeneic Stem Cell Transplantation | ||
| Total, other adverse events | Autologous Hematopoietic Stem Cell Transplantation | 0 | 1 |
| Total, other adverse events | Allogeneic Stem Cell Transplantation | 0 | 1 |
| Total, serious adverse events | Autologous Hematopoietic Stem Cell Transplantation | 0 | 1 |
| Total, serious adverse events | Allogeneic Stem Cell Transplantation | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: Presence of Toxicity | Trial comparisons |
| Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: Survival | Trial comparisons |
| Autologous Hematopoietic Stem Cell Transplantation vs Allogeneic Stem Cell Transplantation: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00282438
GET https://conductscience.org/api/trials/v1/NCT00282438/registered